This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Rand, J. H. Search for Related Content PubMed PubMed Citation Articles by Rand, J. H. Related Collections Thrombophilia Thrombosis risk factors

(Circulation Research. 2002;90:29.)
© 2002 American Heart Association, Inc.

Reviews

Molecular Pathogenesis of the Antiphospholipid Syndrome

Jacob H. Rand

From the Thrombosis and Hemostasis Section, Hematology Division, Department of Medicine, Mount Sinai School of Medicine, New York, NY.

Correspondence to Jacob H. Rand, Hematology Division, Mount Sinai School of Medicine, Box 1079, 5 E 98th St, New York, NY 10029. E-mail jacob.rand{at}mssm.edu

Abstract

The antiphospholipid (aPL) syndrome is an acquired autoimmune disorder of unknown etiology in which patients present with thrombosis together with laboratory evidence for antibodies in blood that recognize anionic phospholipid-protein complexes. The main antigenic target for the aPL antibodies has been identified to be ß₂ glycoprotein I (ß₂GPI), a phospholipid-binding protein. The high affinity of aPL antibody-ß₂GPI complex for phospholipid membranes seems to be a critical step in the mechanism of this disease. This review focuses on some of the major mechanisms that have been proposed to explain this disorder.

Key Words: antiphospholipid antibodies • anticardiolipin antibodies • lupus anticoagulants • thrombosis • annexins

This article has been cited by other articles:

				E Cockrell, R. Espinola, and K. McCrae Annexin A2: biology and relevance to the antiphospholipid syndrome Lupus, October 1, 2008; 17(10): 944 - 952. [Abstract] [PDF]

				P. Soltesz, H. Der, K. Veres, R. Laczik, S. Sipka, G. Szegedi, and P. Szodoray Immunological features of primary anti-phospholipid syndrome in connection with endothelial dysfunction Rheumatology, September 9, 2008; (2008) ken349v1. [Abstract] [Full Text] [PDF]

				J. H. Rand, X.-X. Wu, A. S. Quinn, P. P. Chen, J. J. Hathcock, and D. J. Taatjes Hydroxychloroquine directly reduces the binding of antiphospholipid antibody-{beta}2-glycoprotein I complexes to phospholipid bilayers Blood, September 1, 2008; 112(5): 1687 - 1695. [Abstract] [Full Text] [PDF]

				S. K. Vora, R. A. Asherson, and D. Erkan Catastrophic antiphospholipid syndrome. J Intensive Care Med, May 1, 2006; 21(3): 144 - 159. [Abstract] [PDF]

				J. Zhang and K. R. McCrae Annexin A2 mediates endothelial cell activation by antiphospholipid/anti-{beta}2 glycoprotein I antibodies Blood, March 1, 2005; 105(5): 1964 - 1969. [Abstract] [Full Text] [PDF]

				A. Cederholm, E. Svenungsson, K. Jensen-Urstad, C. Trollmo, A.-K. Ulfgren, J. Swedenborg, G.-Z. Fei, and J. Frostegard Decreased Binding of Annexin V to Endothelial Cells: A Potential Mechanism in Atherothrombosis of Patients With Systemic Lupus Erythematosus Arterioscler. Thromb. Vasc. Biol., January 1, 2005; 25(1): 198 - 203. [Abstract] [Full Text] [PDF]

				J. H. Rand, X.-X. Wu, R. Lapinski, W. L. van Heerde, C. P. Reutelingsperger, P. P. Chen, and T. L. Ortel Detection of antibody-mediated reduction of annexin A5 anticoagulant activity in plasmas of patients with the antiphospholipid syndrome Blood, November 1, 2004; 104(9): 2783 - 2790. [Abstract] [Full Text] [PDF]

				P. Lieby, V. Poindron, S. Roussi, C. Klein, A.-M. Knapp, J.-C. Garaud, M. Cerutti, T. Martin, and J.-L. Pasquali Pathogenic antiphospholipid antibody: an antigen-selected needle in a haystack Blood, September 15, 2004; 104(6): 1711 - 1715. [Abstract] [Full Text] [PDF]

				M. A. Ozturk, I. C. Haznedaroglu, M. Turgut, and H. Goker Current Debates in Antiphospholipid Syndrome: The Acquired Antibody-Mediated Thrombophilia Clinical and Applied Thrombosis/Hemostasis, April 1, 2004; 10(2): 89 - 126. [Abstract] [PDF]

				D. Tanne, S.R. Levine, R.L. Brey, H. Lin, and B.C. Tilley Antiphospholipid-protein antibodies and acute ischemic stroke in the NINDS rt-PA Stroke Trial Neurology, October 28, 2003; 61(8): 1158 - 1159. [Full Text] [PDF]

				J. H. Rand, X.-X. Wu, A. S. Quinn, P. P. Chen, K. R. McCrae, E. G. Bovill, and D. J. Taatjes Human Monoclonal Antiphospholipid Antibodies Disrupt the Annexin A5 Anticoagulant Crystal Shield on Phospholipid Bilayers: Evidence from Atomic Force Microscopy and Functional Assay Am. J. Pathol., September 1, 2003; 163(3): 1193 - 1200. [Abstract] [Full Text] [PDF]

				T. E. Warkentin, W. C. Aird, and J. H. Rand Platelet-Endothelial Interactions: Sepsis, HIT, and Antiphospholipid Syndrome Hematology, January 1, 2003; 2003(1): 497 - 519. [Abstract] [Full Text] [PDF]

				M. Jankowski, I. Vreys, C. Wittevrongel, D. Boon, J. Vermylen, Marc. F. Hoylaerts, and J. Arnout Thrombogenicity of beta 2-glycoprotein I-dependent antiphospholipid antibodies in a photochemically induced thrombosis model in the hamster Blood, January 1, 2003; 101(1): 157 - 162. [Abstract] [Full Text] [PDF]

				F. L Ruberg and J. Loscalzo Prothrombotic determinants of coronary atherothrombosis Vascular Medicine, November 1, 2002; 7(4): 289 - 299. [Abstract] [PDF]